Natasha Giles
Psychiatric/Mental Health · Loganville, GANPI 1598231458
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,164 of the $21,041 with a category attached, or 62.6%. 25 manufacturers reported payments, led by AbbVie at 46.3% of the total. 2025 is the largest year on record at $9,242, 8.6 times the $1,070 reported in 2021. Among psychiatric/mental health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 694 payments — averaging $30.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$1K
- Neurocrine Biosciences, Inc.$891
- Lundbeck LLC$869
- plus $5K from 19 others
What the payments were for
- Speaking & faculty fees$7,00033%
- Travel & lodging$8264%
- Food & beverage$13,16463%
- Education$500%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 212 | $9,745 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 110 | $2,613 |
| Otsuka America Pharmaceutical, Inc. | 55 | $1,118 |
| Johnson & Johnson | 30 | $1,050 |
| Neurocrine Biosciences, Inc. | 42 | $891 |
| Lundbeck LLC | 43 | $869 |
| Alkermes, Inc. | 35 | $775 |
| Teva Pharmaceuticals USA, Inc. | 36 | $595 |
| Axsome Therapeutics, Inc. | 15 | $513 |
| Corium, LLC | 27 | $435 |
| Ironshore Pharmaceuticals Inc. | 17 | $397 |
| Supernus Pharmaceuticals, Inc. | 10 | $386 |
| Vanda Pharmaceuticals Inc. | 15 | $364 |
| Tris Pharma Inc | 7 | $248 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $248 |
| E.r. Squibb & Sons, L.L.C. | 6 | $229 |
| Biogen | 1 | $109 |
| Bausch Health US, LLC | 5 | $105 |
| Noven Pharmaceuticals, Inc. | 1 | $95 |
| Sunovion Pharmaceuticals Inc. | 4 | $74 |
| Noven Therapeutics, LLC | 3 | $65 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Collegium Pharmaceutical, Inc. | 2 | $32 |
| Indivior Inc. | 1 | $26 |
| OWP Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$7,650
- CAPLYTA$835
- QELBREE$240
- INVEGA SUSTENNA$230
- Auvelity$221
- SPRAVATO$133
- Quillivant$125
- Dyanavel XR$125
- Quillichew ER$125
- COBENFY$122
- ABILIFY MAINTENA$115
- ABILIFY ASIMTUFII$115
- Fanapt$113
How this compares
$21,041 in reported general payments places this provider in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 24 | $151,064 |
| CaplytaLumateperone Tosylate | 23 | $49,830 |
| VraylarCariprazine Hcl | 17 | $23,159 |
| Quetiapine Fumarate | 93 | $1,247 |
| Clonazepam | 123 | $884 |
| Olanzapine | 37 | $881 |
| Clozapine | 11 | $751 |
| Aripiprazole | 30 | $704 |
| Oxcarbazepine | 11 | $678 |
| Ziprasidone Hcl | 13 | $602 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 16 | $572 |
| Prazosin Hcl | 23 | $439 |
| Lamotrigine | 53 | $421 |
| Bupropion XlBupropion Hcl | 21 | $286 |
| Duloxetine Hcl | 21 | $246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $595 | $151,06424 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,613 | $49,83023 claims |
| AbbVieVraylar | $9,745 | $23,15917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatric/mental health providers in Georgia.
Other psychiatric/mental health in Loganville
- Phyillis Kennedy-HowellBarney$673K
- Jessica OliverThomasville$233K
- Sherri KrollBrunswick$155K
- Taylor LeblancAlbany$48K
- Greta HeckmannDalton$28K
- Matthew DowdyWoodstock$25K
- Darrick SealeyWarner Robins$17K
- Olufunke AdewunmiSmyrna$13K
- Bradley MosherSuwanee$13K
- Mia MisonSuwanee$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.